Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Neoadjuvant Study of Encorafenib With Binimetinib in Patients With Resectable Locoregional Metastases From Cutaneous or Unknown Primary Melanoma (Stages III N1B/C/D)

NCT04221438 is registered in ClinicalTrials.gov with ECOG-ACRIN Cancer Research Group as lead sponsor.

NCT NCT04221438
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04221438 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Neoadjuvant Study of Encorafenib With Binimetinib in Patients With Resectable Locoregional Metastases From Cutaneous or Unknown Primary Melanoma (Stages III N1B/C/D)
Lead sponsor
ECOG-ACRIN Cancer Research Group
Phase
Phase 2
Overall status
Terminated
Start date
September 22, 2021
Completion date
January 31, 2025
Enrollment
3 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma of unknown primary, metastatic malignant neoplasm in lymph node, pathologic stage iiib cutaneous melanoma ajcc v8, pathologic stage iiic cutaneous melanoma ajcc v8, pathologic stage iiid cutaneous melanoma ajcc v8, recurrent cutaneous melanoma